Oric Pharmaceuticals to present rinzimetostat data at AACR2026
Oric Pharmaceuticals announced that two preclinical abstracts detailing the potential of rinzimetostat (ORIC-944) for prostate cancer treatment have been accepted for poster presentation at the ...